Last edition
News about Regulation
Government Simplifies Drug Import Rules for Testing and Analysis
The Government has proposed amendments to the Drugs Rules, 1945, introducing an acknowledgement-based system to simplify the import of drugs for examination, testing, analysis, and non-clinical research.
Regulation | 29/06/2026 | By News Bureau | 142
Lupin Receives US FDA Tentative Approval for Enzalutamide Tablets
Lupin has received tentative US Food and Drug Administration (FDA) approval for Enzalutamide tablets in 40 mg, 80 mg, 120 mg, and 160 mg strengths.
Regulation | 29/06/2026 | By News Bureau | 131
CHMP Recommends Lilly's Jaypirca for CLL Treatment in EU
CHMP has recommended Lilly’s Jaypirca (pirtobrutinib) for EU approval in adults with chronic lymphocytic leukemia (CLL), potentially expanding its use across all lines of therapy.
Regulation | 29/06/2026 | By News Bureau | 143
US FDA Approves KEYTRUDA and KEYTRUDA QLEX, Each with Trodelvy
The US Food and Drug Administration (FDA) has approved KEYTRUDA and KEYTRUDA QLEX in combination with Trodelvy as first-line treatment for adults with PD-L1-positive (CPS ≥10) advanced Triple-Negative Breast Cancer (TNBC).
Regulation | 26/06/2026 | By News Bureau | 240
The Union Health Ministry has expanded its QR code-based drug traceability framework to include vaccines, antimicrobials, NDPS medicines, and anti-cancer drugs, strengthening authentication and supply chain transparency.
Regulation | 25/06/2026 | By News Bureau | 136
The Central Drugs Standard Control Organisation (CDSCO) has clarified the regulatory framework for formulation intermediates, specifying which products require central approval under the NDCT Rules, 2019 and which can be licensed by State Licensing Authorities (SLAs).
Regulation | 25/06/2026 | By News Bureau | 200
EU Approves Sanofi's Cenrifki (Tolebrutinib) for Multiple Sclerosis
The European Commission (EC) has approved Sanofi’s Cenrifki (tolebrutinib) as the first disability-targeting treatment for adults with Secondary Progressive Multiple Sclerosis (SPMS) without relapses.
Regulation | 25/06/2026 | By News Bureau | 282
US FDA and EMA Accept Cemdisiran Regulatory Submissions for Generalised Myasthenia Gravis
The FDA and EMA have accepted regulatory submissions for cemdisiran to treat generalised Myasthenia Gravis (gMG). If approved, it could become the first siRNA therapy for gMG with convenient quarterly subcutaneous dosing.
Regulation | 25/06/2026 | By News Bureau | 356
EU Approves Chiesi's LOJUXTA for Pediatric HoFH Patients
The European Commission has approved Chiesi’s LOJUXTA (lomitapide) for children aged 5 years and older with Homozygous Familial Hypercholesterolaemia (HoFH), expanding treatment options for this ultra-rare genetic disorder.
Regulation | 25/06/2026 | By News Bureau | 112
DoP Seeks Stakeholder Feedback on GTE Medical Device Exemption Amendments
The Department of Pharmaceuticals (DoP) has invited stakeholder comments on proposed amendments to the Global Tender Enquiry (GTE) exemption list for medical devices. Feedback can be submitted until July 15, 2026.
Regulation | 24/06/2026 | By News Bureau | 159
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy